Explain this page
Arphra AIPlain-English read on Eli Lilly and Company’s valuation06-03today
- Eli Lilly Takes Another Stab at the Market for Painkillers. This Attempt Might Work.9h
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL2d
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL2d
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL2d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$2,406.37
+114.38% vs spot
Recommendation
Strong Buy
17 of 19 methods
Method spread
2bull14bear
±5% threshold
Analyst PT consensus: $1,266.17 (+12.80%)
Candlestick · 1Y
Open in chart workstation →LLY
1,129+39.84%H 1,175L 623.78MA50 996.39MA200 958.35Avg vol 3.6M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.61% | -1.51% | +11.70% | +13.48% | +6.47% | +4.45% | +39.00% | +150.72% | +408.47% | +1411.78% | +39846.62% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$23.84M
10 txns
Net flow
−$23.84M
Aftermarket
LiveLast trade
$1123.00
129 sh
Bid
$1122.11
3 sh
Ask
$1123.00
1 sh
Spread
$0.890
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $19.8B | $7.4B | $8.26 |
| Q4 Dec 2025 | $19.29B | $6.64B | $7.39 |
| Q3 Sep 2025 | $17.6B | $5.58B | $6.21 |
| Q2 Jun 2025 | $15.56B | $5.66B | $6.29 |
| Q1 Mar 2025 | $12.73B | $2.76B | $3.06 |
| Q4 Dec 2024 | $13.53B | $4.41B | $4.88 |
Sector & industry today
LiveSectors
- Energy+0.42%
- Consumer Cyclical+0.27%
- Basic Materials+0.27%
- Industrials+0.22%
- Consumer Defensive+0.09%
- Real Estate-0.34%
- Financial Services-0.45%
- Utilities-0.49%
- Healthcare-0.92%
- Communication Services-1.12%
- Technology-2.11%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-1.17%
- Electronic Gaming & Multimedia+7.50%
- Biotechnology-3.87%
- Hardware, Equipment & Parts-3.62%
- Communication Equipment-3.51%
- Department Stores-2.85%
- Medical - Equipment & Services+2.65%
- Apparel - Manufacturers-2.63%
- Independent Power Producers+2.40%
- Semiconductors-2.37%
- Trucking-2.33%
- Oil & Gas Drilling-2.15%
Analyst view
DB · price_targets + analyst_gradesConsensus target
$1,266.17
+12.99% upside
Low
$1,119.00
Median
$1,270.00
High
$1,400.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Eli Lilly Takes Another Stab at the Market for Painkillers. This Attempt Might Work.barrons.com·Jun 16, 2026
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLLgurufocus.com·Jun 14, 2026
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLLprnewswire.com·Jun 14, 2026
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLLprnewswire.com·Jun 14, 2026
- Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meetinggurufocus.com·Jun 13, 2026
- Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meetingprnewswire.com·Jun 13, 2026
- Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meetingprnewswire.com·Jun 13, 2026
- Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Knowzacks.com·Jun 12, 2026
Recent analyst activity
DB- Jun 09, 2026GradeBuy → BuyEli Lilly price target raised to $1,350 from $1,330 at JefferiesJefferies
- Jun 09, 2026PT$1350.00Eli Lilly price target raised to $1,350 from $1,330 at JefferiesJefferies
- Jun 08, 2026GradeOutperform → OutperformBernstein SocGen Reiterates Outperform Rating on Eli Lilly (LLY)Bernstein
- Jun 05, 2026GradeOverweight → OverweightMorgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'Morgan Stanley
Peers
Total assets
$112.48B
Total debt
$42.5B
Cash & equiv
$7.16B
Operating CF
$16.81B
Free cash flow
$8.97B
Buybacks
-$4.11B
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
LILLY ENDOWMENT INC other: Former 10% Shareholder | Sell | 2,208 | $2.2M | May 06, 2026 |
LILLY ENDOWMENT INC other: Former 10% Shareholder | Sell | 13,620 | $13.55M | May 06, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 1,070 | $1.16M | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 1,322 | $1.45M | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 895 | $971.17K | Jan 07, 2026 |
LILLY ENDOWMENT INC 10 percent owner | Sell | 930 | $1.01M | Jan 07, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $65.18B | $29.7B | $20.64B | $22.95 | +31.66% |
| FY 2024 | $45.04B | $17.5B | $10.59B | $11.71 | +23.51% |
| FY 2023 | $34.12B | $10.79B | $5.24B | $5.80 | +15.36% |
| FY 2022 | $28.54B | $8.65B | $6.24B | $6.57 | +21.88% |
| FY 2021 | $28.32B | $7.93B | $5.58B | $5.85 | +19.71% |